Medical oncologist James Reeves, MD, a member of the Florida Cancer Specialists & Research Institute (FCS) Clinical Research Team, is co-author of an abstract entitled “Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).”
Lucio Gordan MD, President and Managing Physician of Florida Cancer Specialists & Research Institute (FCS) and Michael Diaz, MD, Assistant Managing Physician of FCS, are two of the authors of a comprehensive and detailed review on the advisability and efficiency of the current reimbursement methodology in use for Medicare Part B.
Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders are the co-authors of 32 research studies that will be presented at the American Society of Clinical Oncology (ASCO®) 2021 Annual Meeting being held June 4 – 8, 2021.
Medical oncologist Syed Zafar MD, who practices at three Florida Cancer Specialists & Research Institute (FCS) locations in Lee County, is co-author of a new study entitled “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.”
Julio Lautersztain, MD, medical oncologist who practices at Florida Cancer Specialists & Research Institute (FCS) locations in Tampa and Brandon, is co-author of a new study entitled “Novel mechanism of hereditary pyropoikilocytosis phenotype due to co‐inheritance of β globin and α spectrin mutations.”
Pareshkumar Patel, MD, medical oncologist with Florida Cancer Specialists & Research Institute (FCS), is the recipient of the 2021 FLASCO Advocate of the Year Award.
Physicians and leaders of Florida Cancer Specialists & Research Institute (FCS) are participating in the Florida Society of Clinical Oncology (FLASCO) 2021 Business of Oncology Summit & Spring Session being held in Kissimmee, FL on April 16 & 17.
Physicians, clinicians and administrative leaders of Florida Cancer Specialists & Research Institute (FCS) will be participating in the virtual 2021 Community Oncology Conference hosted by the Community Oncology Alliance (COA) on April 8 & 9, 2021.
FCS Top News Updates
FCS Real-World Evidence Abstract Highlights Progress and Gaps in Biomarker Testing for Lung Cancer
FCS Study Finds Comparable Quality and Safety Outcomes in CAR T-Cell Therapy Across Accredited and Non-Accredited Centers, Highlighting Care Location as Key Driver of Patient Access and Experience
James Reeves, MD Co-Authors Abstract Evaluating Abemaciclib Combined with Adjuvant Endocrine Therapy in Patients with High Risk Early Breast CancerMedical oncologist James Reeves, MD, a member of the Florida Cancer Specialists & Research Institute (FCS) Clinical Research Team, is co-author of an abstract entitled “Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).”
Lucio Gordan, MD and Michael Diaz, MD Are Co-Authors of In-Depth Review on Medicare Part B ReimbursementLucio Gordan MD, President and Managing Physician of Florida Cancer Specialists & Research Institute (FCS) and Michael Diaz, MD, Assistant Managing Physician of FCS, are two of the authors of a comprehensive and detailed review on the advisability and efficiency of the current reimbursement methodology in use for Medicare Part B.
Florida Cancer Specialists & Research Institute Studies Featured at ASCO® 2021 Annual MeetingFlorida Cancer Specialists & Research Institute (FCS) physicians and senior leaders are the co-authors of 32 research studies that will be presented at the American Society of Clinical Oncology (ASCO®) 2021 Annual Meeting being held June 4 – 8, 2021.
Syed Zafar, MD Co-Authors Study on Adjuvant Nivolumab in Esophageal/Gastroesophageal Junction CancerMedical oncologist Syed Zafar MD, who practices at three Florida Cancer Specialists & Research Institute (FCS) locations in Lee County, is co-author of a new study entitled “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.”
Julio Lautersztain, MD Co-Authors Study on Novel Co-Inheritance of Beta Globin and Spectrin MutationsJulio Lautersztain, MD, medical oncologist who practices at Florida Cancer Specialists & Research Institute (FCS) locations in Tampa and Brandon, is co-author of a new study entitled “Novel mechanism of hereditary pyropoikilocytosis phenotype due to co‐inheritance of β globin and α spectrin mutations.”
Florida Cancer Specialists & Research Institute Medical Oncologist Paresh Patel, MD Named 2021 FLASCO “Advocate of the Year”Pareshkumar Patel, MD, medical oncologist with Florida Cancer Specialists & Research Institute (FCS), is the recipient of the 2021 FLASCO Advocate of the Year Award.
Florida Cancer Specialists & Research Institute Physicians Featured Speakers at Community Oncology Alliance Spring SessionPhysicians, clinicians and administrative leaders of Florida Cancer Specialists & Research Institute (FCS) will be participating in the virtual 2021 Community Oncology Conference hosted by the Community Oncology Alliance (COA) on April 8 & 9, 2021.